COMPASS Pathways plc, a biotechnology company focused on mental health innovation, reported a net loss of $17.864 million for the three months ended March 31, 2025, a significant improvement compared to a net loss of $35.187 million for the same period in 2024. This improvement was largely due to a $19.460 million fair value change of warrant liabilities and an increased R&D tax credit of $8.448 million. The company continues to incur operating losses as it advances its Phase 3 program for COMP360 psilocybin treatment in TRD, with total operating expenses increasing to $49.616 million from $38.573 million in the prior year.

Compass Pathways reported a net loss of $43.3 million for the quarter ended December 31, 2024. The company's cash and cash equivalents were $165.1 million as of December 31, 2024. Phase 3 COMP005 trial in participants with treatment resistant depression (TRD) 6-week top-line data on track for second quarter 2025.

Compass Pathways reported a net loss of $38.5 million for the third quarter of 2024. The company is prioritizing its COMP360 program and reducing its workforce by approximately 30%. The company's cash and cash equivalents were $207 million as of September 30, 2024.

Compass Pathways reported a net loss of $38.1 million for the second quarter of 2024, with research and development expenses increasing to $29.1 million. The company's cash and cash equivalents totaled $228.6 million as of June 30, 2024.

Compass Pathways reported a net loss of $35.2 million, or $0.55 loss per share, for the three months ended March 31, 2024. The company's cash and cash equivalents were $262.9 million as of March 31, 2024.

Compass Pathways reported a net loss of $32.5 million for the three months ended December 31, 2023, compared to a net loss of $30.9 million for the same period in 2022. Cash and cash equivalents were $220.2 million as of December 31, 2023.

COMPASS Pathways announced its Q3 2023 financial results, highlighting the ongoing Phase 3 program for COMP360, a strong cash position of $248.0 million, and a recent private placement financing of up to $285 million. The company's net loss for the quarter was $33.4 million, or $0.67 loss per share.

COMPASS Pathways reported a net loss of $28.3 million for the second quarter of 2023, with cash and cash equivalents totaling $148.2 million as of June 30, 2023. The company's COMP360 phase 3 trials are ongoing and on track, and they secured a term loan facility of up to $50 million.

COMPASS Pathways reported a net loss of $24.2 million for the first quarter of 2023. The Phase 3 pivotal program for COMP360 is underway, and a CPT III code for in-person psychedelic therapy support has been accepted by the American Medical Association. The company's cash position as of March 31, 2023, was $117.1 million, with an additional $26.9 million raised through an ATM facility to date in the second quarter.

COMPASS Pathways announced its Q4 and year-end 2022 financial results, highlighted by the commencement of its Phase 3 pivotal program for COMP360 psilocybin therapy in treatment-resistant depression. The company reported a net loss for the quarter of $30.9 million, or $0.73 loss per share, and a cash position of $143.2 million as of December 31, 2022.

COMPASS Pathways announced the finalization of its Phase 3 pivotal program design and progress in clinical trials, including the publication of Phase 2b trial data in The New England Journal of Medicine. The company's cash position at the end of the quarter was $173.1 million. The net loss for the quarter was $18.4 million, or $0.43 loss per share.

COMPASS Pathways reported a net loss for the quarter ended December 31, 2021, was $25.7 million, or $0.61 loss per share. The company's cash and cash equivalents were $273.2 million as of December 31, 2021.